Seminars in Oncology
Volume 29, Issue 6 , Pages 531-545 , December 2002

Complementary and alternative medicine: Opportunities and challenges for cancer management and research

References 

  1. The National Center for Complementary and Alternative Medicine . Expanding Horizons of Healthcare: The Five-Year NCCAM Strategic Plan 2001-2005. http://NCCAM.Nih.Gov/Nccam/StrategicMarch 28 2001; accessed
  2. Arab L. Epidemiologic challenges in the study of the efficacy and safety of medicinal herbs. Public Health Nutr. 2000;3:453–457
  3. Eisenberg D, Davis R, Ettner S, et al.  Trends in alternative medicine use in the United States, 1990-1997: Results of a follow-up national survey. JAMA. 1998;280:1569–1575
  4. Eisenberg D, Kessler RC, Foster C, et al.  Unconventional medicine in the United States: Prevalence, costs, and patterns of use. N Engl J Med. 1993;328:246–252
  5. Wolsko P, Eisenberg D, Davis R, et al.  Insurance coverage, medical conditions, and visits to alternative medicine providers: Results of a national survey. Arch Intern Med. 2002;162:281–287
  6. Ernst E, Cassileth BR. The prevalence of complementary/alternative medicine in cancer. A systematic review. Cancer. 1998;83:777–782
  7. Kelly KM, Jacobson JS, Kennedy DO, et al.  Use of unconventional therapies by children with cancer at an urban medical center. J Pediatr Hematol Oncol. 2000;22:412–426
  8. Richardson MA, Ramirez T, Palmer JL, et al.  Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol. 2000;18:2505–2514
  9. Lee MM, Lin SS, Wrensch MR, et al.  Alternative therapies used by women with breast cancer in four ethnic populations. J Natl Cancer Inst. 2000;92:42–47
  10. Crocetti E, Crotti N, Feltrin A, et al.  The use of complementary therapies by breast cancer patients attending conventional treatment. Eur J Cancer. 1998;34:324–328
  11. Munstedt K, Kirsch K, Milch W, et al.  Unconventional cancer therapy: Survey of patients with gynecological malignancy. Arch Gynecol Obstet. 1996;258:81–88
  12. Burstein HJ, Gelber S, Guadagnoli E, et al.  Use of alternative medicine by women with early-stage breast cancer. JAMA. 1999;340:1739–1773
  13. Verhoef MJ, Hagen N, Pelletier G, et al.  Alternative therapy use in neurologic diseases. Neurology. 1999;52:617–622
  14. Adler SR, Foskett JR. Disclosing complementary and alternative medicine use in the medical encounter: A qualitative study in women with breast cancer. J Fam Pract. 1999;48:453–458
  15. Boon H, Stewart M, Kennard M, et al.  Use of complementary/alternative medicine by breast cancer survivors in ontario: prevalence and perceptions. J Clin Oncol. 2000;18:2515–2521
  16. Lippert M, McClain R, Boyd J, et al.  Alternative medicine use in patients with localized prostate carcinoma treated with curative intent. Cancer. 1999;86:2642–2648
  17. Sollner W, Maislinger S, DeVries A, et al.  Use of complementary and alternative medicine by cancer patients is not associated with perceived distress or poor compliance with standard treatment but with active coping behavior. Cancer. 2000;89:873–880
  18. Rees R, Feigel I, Vickers A, et al.  Prevalence of complementary therapy use by women with breast cancer: A population-based survey. Eur J Cancer. 2000;36:1359–1364
  19. Moschen R, Kemmler G, Schweigkofler H, et al.  Use of alternative/complementary therapy in breast cancer patients—A psychological perspective. Support Care Cancer. 2001;9:267–274
  20. Gotay C, Hara W, Issell B, et al.  Use of complementary and alternative medicine in Hawaii cancer patients. Hawaii Med J. 1999;58:94–95
  21. Sparber A, Bauer L, Curt G, et al.  Use of complementary medicine by adult patients participating in cancer clinical trials. Oncol Nurs Forum. 2000;27:623–630
  22. Weis J, Bartsch H, Hennies F, et al.  Complementary medicine in cancer patients: Demand, patients' attitude, and psychological belief. Onkologie. 1998;21:144–149
  23. Risberg T, Lund E, Wist E, et al.  The use of non-proven therapy among patients treated in Norwegian oncological departments: A cross-sectional national multicenter study. Eur J Cancer. 1995;31A:1785–1789
  24. Begbie SD, Kerestes ZL, Bell DR. Patterns of alternative medicine use by cancer patients. Med J Aust. 1996;165:545–548
  25. Sollner W, Zingg-Schir M, Rumpold G, et al.  Attitude toward alternative therapy, compliance with standard treatment, and need for emotional support in patients with melanoma. Arch Dermatol. 1997;133:316–321
  26. Fernandez CV, Stutzer CA, MacWilliam L, et al.  Alternative and complementary therapy use in pediatric oncology patients in British Columbia: Prevalence and reasons for use and nonuse. J Clin Oncol. 1998;16:1279–1286
  27. Sawyer MG, Gannoni AF, Toogood IR, et al.  The use of alternative therapies by children with cancer. Med J Aust. 1994;160:320–322
  28. Oneschuk D, Fennell L, Hanson J, et al.  The use of complementary medications by cancer patients attending an outpatient pain and symptom clinic. J Palliat Care. 1998;14:21–26
  29. Lerner IJ, Kennedy BJ. The prevalence of questionable methods of cancer treatment in the United States. CA Cancer J Clin. 1992;42:181–191
  30. DiPaola RS, Zhang H, Lambert GH, et al.  Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. N Engl J Med. 1998;339:785–791
  31. Ernst E. Harmless herbs? A review of the recent literature. Am J Med. 1998;104:170–178
  32. Labriola D, Livingston R. Possible interactions between dietary antioxidants and chemotherapy. Oncology. 1999;19:1003–1008
  33. Lamson D, Brignall M. Antioxidants in cancer therapy; their actions and interactions with oncologic therapies. Altern Med Rev. 1999;4:304–329
  34. Weijl NI, Cleton FJ, Osanto S. Free radicals and antioxidants in chemotherapy-induced toxicity. Cancer Treat Rev. 1997;23:209–240
  35. Zeisel S, Salganik R. Special commentary: Antioxidants and nutrition support. Curr Opin Clin Nutr Metab Care. 1999;2:1–3
  36. Conklin K. Dietary antioxidants during cancer chemotherapy: Impact on chemotherapeutic effectiveness and development of side effects. Nutr Cancer. 2000;37:1–18
  37. Washburn A. Complementary therapies: A survey of NCI cancer patient educators. Cancer Pract. 2000;8:143–144
  38. Slevin ML, Stubbs L, Plant HJ, et al.  Attitudes to chemotherapy: Comparing views of patients with cancer with those of doctors, nurses, and general public. Br Med J. 1990;300:1458–1460
  39. Jeffrey D. Education in palliative care: A qualitative evaluation of the present state and the needs of general practitioners and community nurses. Eur J Cancer Care (Engl). 1994;3:67–74
  40. Stoll BA. Can unorthodox cancer therapy improve quality-of-life?. Ann Oncol. 1993;4:121–123
  41. Pan C, Morrison R, Ness J, et al.  Complementary and alternative medicine in the management of pain, dyspnea, and nausea and vomiting near the end of life: a systematic review. J Pain Symptom Manage. 2000;20:374–387
  42. Wallace KG. Analysis of recent literature concerning relaxation and imagery interventions for cancer pain. Cancer Nurs. 1997;20:79–87
  43. Tagliaferri M, Cohen I, Tripathy D. Complementary and alternative medicine in early-stage breast cancer. Semin Oncol. 2001;28:121–134
  44. Consensus Development Panel on Acupuncture NIH. Acupuncture. JAMA. 1998;280:1518–1524
  45. Shen J, Wenger N, Glaspy J, et al.  Electroacupuncture for control of myeloablative chemotherapy-induced emesis: A randomized controlled trial. JAMA. 2000;284:2755–2761
  46. Richardson MA, Allen C, Ezzo J, et al.  Acupuncture for chemotherapy induced nausea and vomiting in cancer patients (Protocol for a Cochrane Review), in: The Cochrane Library. Oxford, UK: Update Software; 2002; issue 3
  47. McMillan CM, Dundee JW. The role of transcutaneous electrical stimulation of Neiguan anti-emetic acupuncture point in controlling sickness after chemotherapy. Physiotherapy. 1991;77:499–502
  48. Schneider K, Leonard E. A matter of choice. People. April 30, 2001;72–81
  49. Bussing A. Mistletoe: A story with an open end. Anticancer Drugs. 1997;8:S1–S2 (suppl)
  50. Hajto T, Hostanska K, Gabius HJ. Modulatory potency of the beta-galactoside-specific lectin from mistletoe extract (Iscador) on the host defense system in vivo in rabbits and patients. Cancer Res. 1989;49:4803–4808
  51. Hajto T, Hostanska K, Frei K, et al.  Increased secretion of tumor necrosis factor alpha, interleukin 1, and interleukin 6 by human mononuclear cells exposed to b-galactoside-specific lectin from clinically applied mistletoe extract. Cancer Res. 1990;50:3322–3326
  52. Schultze JL, Stettin A, Berg PA. Demonstration of specifically sensitized lymphocytes in patients treated with an aqueous mistletoe extract (Viscum album L.). Klin Wochenschr. 1991;69:397–403
  53. Muller EZ, Anderer FA. A Viscum album oligosaccharide activating human natural cytotoxicity is an interferon gamma inducer. Cancer Immunol Immunother. 1990;32:221–227
  54. Kleijnen J, Knipschild P. Mistletoe treatment for cancer. Review of controlled clinical trials. Phytomedicine. 1994;1:255–260
  55. Kaegi E. Unconventional therapies for cancer: 3. Iscador. Task Force on Alternative Therapies of the Canadian Breast Cancer Research Initiative. CMAJ. 1998;158:1157–1159
  56. Steuer-Vogt MK, Bonkowsky V, Ambrosch P, et al.  The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients: A randomised controlled clinical trial. Eur J Cancer. 2001;37:23–31
  57. Kleeberg U, Brocker E, Lejeune F, et al.  Adjuvant trial in melanoma patients comparing rIFN-alpha to rIFN-gamma to Iscador to a control group after curative resection of high-risk primary or regional lymph node metastasis (EORTC 18871). Eur J Cancer. 1999;35(suppl 4):S82; abstr 264
  58. Grossarth-Maticek R, Kiene H, Baumgartner S, et al.  Use of Iscador, an extract of European mistletoe (viscum album), in cancer treatment: Prospective nonrandomized and randomized matched-pair studies nested within a cohort study. Altern Ther Health Med. 2001;7:57–78
  59. Marks LS, Di Paola RS, Nelson D, et al.  PC-SPES: Herbal formulation for prostate cancer. Urology. 2002;60:369–377
  60. Darzynkiewicz Z, Traganos F, Wu J, et al.  Chinese herbal mixture PC SPES in treatment of prostate cancer. Int J Oncol. 2000;17:729–736
  61. de la Taille A, Hayek O, Buttyan R, et al.  Effects of a phytotherapeutic agent, PC-SPES, on prostate cancer: A preliminary investigation on human cell lines and patients. BJU Int. 1999;84:845–850
  62. Pfeifer B, Pirani J, Hamann S, et al.  PC-SPES, a dietary supplement for the treatment of hormone-refractory prostate cancer. BJU Int. 2000;85:481–485
  63. Small E, Frohlich M, Bok R, et al.  Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. J Clin Oncol. 2000;18:3595–3603
  64. Sun AS, Ostadal O, Ryznar V, et al.  Phase I/II study of stage III and IV non-small cell lung cancer patients taking a specific dietary supplement. Nutr Cancer. 1999;34:62–69
  65. Sun A, Yeh H, Wang L, et al.  Pilot study of a specific dietary supplement in tumor bearing mice and in stage IIIB and IV non-small cell lung cancer patients. Nutr Cancer. 2001;39:85–95
  66. King LS. Prevention of virus-induced mammary tumors by an orally active pancreas factor. Exp Med Surg. 1965;23:345–347
  67. King LS. A novel method of enhancing antibody production. Southwest Med. 1967;46:222–224
  68. US Congressional Office of Technology Assessment. Washington, DC: US Government Printing Office; 1990;
  69. Gonzalez NJ, Isaacs LL. Evaluation of pancreatic proteolytic enzyme treatment of adenocarcinoma of the pancreas, with nutriton and detoxification support. Nutr Cancer. 1999;32:117–124
  70. Niederhuber JE, Brennan MF, Menck HR. The national cancer data base report on pancreatic cancer. Cancer. 1995;76:1671–1677
  71. Burris HA, Moore MJ, Andersen J, et al.  Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol. 1997;15:2403–2413
  72. National Institutes of Health . Gemcitabine compared with pancreatic enzyme therapy in treating patients who have stage II, stage III, or stage IV pancreatic cancer. accessed May 8, 2001. Web Page. Available at http://www.clinicaltrials.govAugust 1, 2000;
  73. Frichtel H. Chemotherapy with or without Wobe-Mugos E in treating patients with stage II or stage III multiple myeloma. Personal Communication, Medsearch. October 22, 2002;
  74. Klaschka F. Oral Enzymes—New Approach to Cancer Treatment: Immunological Concepts for General and Clinical Practice. Grafelfing, Germany: Forum-Mendizin Verlagsgesellschaft mbH; 1996;
  75. Sakalova A, Dedik L, Gazova S, et al.  Survival analysis of an adjuvant therapy with oral enzymes in multiple myeloma patients. Br J Haematol. 1998;102(suppl 5):353
  76. Sakalova A, Desser L, Bucova M, et al.  Recent immunological approaches and therapy of multiple myeloma. J Health Manage Public Health. 1998;3:47–54
  77. Sakalova A, Chabronova I, Gazova S, et al.  Retrolective cohort study of an additive therapy with an oral enzyme preparation in patients with multiple myeloma. Cancer Chemother Pharmacol. 2001;47:S38–S44 (suppl)
  78. Buiatti E, Arniani S, Verdecchia A, et al.  Results from a historical survey of the survival of cancer patients given Di Bella multitherapy. Cancer. 1999;86:2143–2149
  79. Italian Study Group for the Di Bella Multitherapy Trials . Evaluation of an unconventional cancer treatment (the Di Bella multitherapy): Results of phase II trials in Italy. BMJ. 1999;318:224–228
  80. Ness C. Alternative Therapy for Cancer Welcomed. San Francisco Examiner-Chronicle. October 25, 1998;(D)1
  81. Richardson MA, Tamayo C, Klein A, et al.  Rationale for drug development of herbals in oncology: Clinical, industry, and regulatory perspectives. Drug Info J. 1999;33:1003–1010
  82. Lazarowych N, Pekos P. Use of fingerprinting and marker compounds for identification and standardization of botanical drugs: Strategies for applying pharmaceutical HPLC analysis to herbal products. Drug Info J. 1998;32:497–512
  83. Houghton PJ. Establishing identification criteria for botanicals. Drug Info J. 1998;32:461–469
  84. Kaptchuk TJ. Chinese herbal medicine for irritable bowel syndrome. JAMA. 1999;282:1035–1047
  85. Jadad A, Gagliardi A. Rating health information on the internet. JAMA. 1998;279:611–614
  86. Ernst E, Armstrong N. Lay books on complementary/alternative medicine: A risk factor for good health?. Int J Risk Safety Med. 1998;11:209–215
  87. Ezzo J, Berman B, Vickers A, et al.  Complementary medicine and the Cochrane Collaboration. JAMA. 1998;280:1628–1630
  88. Voelker R. CAM research attempts to separate wheat from chaff. JAMA. 2001;286:156–158
  89. Ernst E. The Desktop Guide to Complementary and Alternative Medicine: An Evidence-Based Approach. New York, NY: Mosby; 2001;
  90. Fontanarosa PB. Alternative medicine meets science. JAMA. 1998;280:1618–1619
  91. Angell M, Kassirer P. Alternative medicine—The risks of untested and unregulated remedies. N Engl J Med. 1998;339:839–841
  92. Tannock IF, Warr DG. Unconventional therapies for cancer: A refuge from the rules of evidence?. Can Med Assoc J. 1998;159:801–802
  93. Holland JC, Geary N, Furman A. Alternative cancer therapies. In:  Holland JC,  Rowland JH editor. Handbook of Psychooncology: Psychological Care of the Patient With Cancer. New York, NY: Oxford University Press; 1989;p. 508–515
  94. Cassileth BR. Unorthodox cancer medicine. Cancer Invest. 1986;4:591–598
  95. Vickers A, Cassileth B, Ernst E, et al.  How should we research unconventional therapies—A panel report from the Conference on Complementary and Alternative Medicine Research Methodology, National Institutes of Health. Intern J Technol Assess Health Care. 1997;13:111–121
  96. Levin JS, Glass TA, Kushi LH, et al.  Quantitative methods in research on complementary and alternative medicine: a methodological manifesto. Med Care. 1997;35:1079–1094
  97. Margolin A, Avants SK, Kleber HD. Investigating alternative medicine therapies in randomized controlled trials. JAMA. 1998;280:1626–1628
  98. Cameron E, Pauling L. Supplemental ascorbate in the supportive treatment of cancer: Reevaluation of prolongation of survival times in terminal human cancer. Proc Natl Acad Sci USA. 1978;75:4538–4542
  99. Cameron E, Pauling L. Cancer and Vitamin C. Menlo Park, CA: Linus Pauling Institute of Science and Medicine; 1979;
  100. Creagan ET, Moertel CG, O'Fallon JR, et al.  Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med. 1979;301:687–690
  101. Moertel CG, Fleming TR, Creagan ET, et al.  High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med. 1985;312:137–141
  102. Loprinzi CL, Kuross SA, O'Fallon JR, et al.  Randomized placebo-controlled evaluation of hydrazine sulfate in patients with advanced colorectal cancer. J Clin Oncol. 1994;12:1121–1125
  103. Kosty MP, Fleishman SB, Herndon JE, et al.  Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: A randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B. J Clin Oncol. 1994;12:1113–1120
  104. Herndon JE, Fleishman S, Kosty MP, et al.  A longitudinal study of quality of life in advanced non-small cell lung cancer: Cancer and Leukemia Group B (CALGB) 8931. Control Clin Trials. 1997;18:286–300
  105. Chlebowski RT, Bulcavage L, Grosvenor M, et al.  Hydrazine sulfate influence on nutritional status and survival in non-small-cell lung cancer. J Clin Oncol. 1990;8:9–15
  106. Hawkins MG, Friedman MA:. National Cancer Institute's evaluation of unconventional cancer treatments. J Natl Cancer Inst. 1992;74:1699–1702
  107. Ernst E. Editorial comment: Mistletoe for cancer?. Eur J Cancer. 2001;37:9–11
  108. Balmer C. Alternative therapies in cancer patient care. Highlights Oncol Pract. 1998;15:83–93
  109. American Cancer Society . American Cancer Society's Guide to Complementary and Alternative Cancer Methods. Atlanta, GA: American Cancer Society; 2000;
  110. The University of Texas M.D . Anderson Cancer Center. Available at: http://www.mdanderson.org/departments/cimerOctober 20 2002; accessed
  111. Kappauf H, Leykauf-Ammon D, Bruntsch U, et al.  Use of and attitudes held towards unconventional medicine by patients in a department of internal medicine/oncology and haematology. Support Care Cancer. 2000;8:314–322
  112. Morris K, Johnson N, Horner L, et al.  A comparison of complementary therapy use between breast cancer patients and patients with other primary tumor sites. Am J Surg. 2000;179:407–411
  113. Ashikaga T, Bosompra K, O'Brien P, et al: Use of complementary and alternative medicine by breast cancer patients: Prevalence, patterns and communication with physicians. Support Care Cancer (in press)
  114. McCurdy E, Spangler J, Wofford M, et al.  Complementary and alternative therapy use in pediatric oncology patients. J Pediatr Hematol Oncol. 2001;A27
  115. Powell C, Dibble S, Dall'era J, et al.  Use of herbs in women diagnosed with ovarian cancer. Int J Gynecol Cancer. 2002;12:214–217
  116. Von Gruenigen V, White L, Kirven M, et al.  A comparison of complementary and alternative medicine use by gynecology and gynecologic oncology patients. Int J Gynecol Cancer. 2000;11:205–209

☆ Address reprint requests to Mary Ann Richardson, DrPH, National Institutes of Health, Center for Alternative and Complementary Medicine, 6707 Democracy Blvd, Suite 106, Bethesda, MD 20892-5475.

☆☆ This is a US government work. There are no restrictions on its use.

PII: S0093-7754(02)50316-X

doi: 10.1053/sonc.2002.50002

Seminars in Oncology
Volume 29, Issue 6 , Pages 531-545 , December 2002

Article Tools

* Image Usage & Resolution